Journal
JOURNAL OF THE NEUROLOGICAL SCIENCES
Volume 362, Issue -, Pages 266-271Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jns.2016.01.046
Keywords
Amyloid; familial amyloid polyneuropathy; tafamidis; transthyretin amyloidosis; TTR Val30Met; TTR non-Val30Met
Categories
Funding
- Pfizer Inc.
- Grants-in-Aid for Scientific Research [26860672, 15K09318, 15K09336] Funding Source: KAKEN
Ask authors/readers for more resources
Introduction: The efficacy and safety of tafamidis in transthyretin (TTR) familial amyloid polyneuropathy (TTR-FAP) were evaluated in this open-label study. Methods: Japanese TTR-FAP patients (n = 10; mean age 60.1 years) received tafamidis meglumine (20 mg daily; median treatment duration 713.5 days). The primary endpoint was TTR stabilization at Week 8. Secondary end-points included Neuropathy Impairment Score-Lower Limb (NIS-LL), Norfolk QOL-DN total quality of life (TQOL), and modified body mass index (mBMI). Results: TTR stabilization was achieved in all patients at Weeks 8 and 26,9 out of 10 patients at Week 52, and 8 out of 10 patients at Week 78. The percentage (95% CI) of NIS-LL responders (increase from baseline in NIS-LL < 2) was 80.0% (44.4, 97.5), 60.0% (26.2, 87.8), and 40.0% (12.2, 73.8) and mean(SD) NIS-LL change from baseline was 2.1 (5.6), 3.6 (4.4), and 33 (4.7), at Weeks 26, 52, and 78, respectively. Mean (SD) changes from baseline in TQOL and mBMI at Weeks 26, 52, and 78 were 11.8 (20.0), 9.1 (12.5), and 10.8 (13.7) for TQOL, and 26.6 (61.9), 64.9 (80.0), and 53.7 (81.4) for mBMI, respectively. Ambulation status was preserved in 4 out of 8 patients at Week 78. Most adverse events (AEs) were mild/moderate, with no discontinuations due to AEs. Conclusions: Tafamidis stabilized TTR, was safe and well-tolerated, and was effective over 1.5 years in slowing neurologic progression and maintaining TQOL and nutrition status in TTR-FAP. (C) 2016 Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available